Joaquim Bellmunt

66.4k total citations · 18 hit papers
651 papers, 30.8k citations indexed

About

Joaquim Bellmunt is a scholar working on Surgery, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, Joaquim Bellmunt has authored 651 papers receiving a total of 30.8k indexed citations (citations by other indexed papers that have themselves been cited), including 422 papers in Surgery, 288 papers in Pulmonary and Respiratory Medicine and 254 papers in Oncology. Recurrent topics in Joaquim Bellmunt's work include Bladder and Urothelial Cancer Treatments (415 papers), Urinary and Genital Oncology Studies (227 papers) and Cancer Immunotherapy and Biomarkers (158 papers). Joaquim Bellmunt is often cited by papers focused on Bladder and Urothelial Cancer Treatments (415 papers), Urinary and Genital Oncology Studies (227 papers) and Cancer Immunotherapy and Biomarkers (158 papers). Joaquim Bellmunt collaborates with scholars based in United States, Spain and France. Joaquim Bellmunt's co-authors include Toni K. Choueiri, Thomas Wiegel, Nicolas Mottet, Steven Joniau, M. Bolla, Daniel P. Petrylak, Malcolm D. Mason, Nicholas J. Vogelzang, Theodorus van der Kwast and Ronald de Wit and has published in prestigious journals such as Nature, New England Journal of Medicine and Nature Medicine.

In The Last Decade

Joaquim Bellmunt

625 papers receiving 30.4k citations

Hit Papers

Pembrolizumab as Second-Line Therapy for Adva... 2009 2026 2014 2020 2017 2014 2013 2010 2016 500 1000 1.5k 2.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
    2017 2.4k citations Joaquim Bellmunt, Ronald de Wit et al. profile →
  2. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer
    2014 1.9k citations Thomas Powles, Yohann Loriot et al. profile →
  3. EAU Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent—Update 2013
    2013 1.5k citations Joaquim Bellmunt et al. European Urology profile →
  4. EAU Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Treatment of Clinically Localised Disease
    2010 1.2k citations Joaquim Bellmunt et al. European Urology profile →
  5. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer
    2016 1.1k citations Joaquim Bellmunt et al. European Urology profile →
  6. First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study
    2017 939 citations Daniel Castellano, Petros Grivas et al. profile →
  7. Phase III Trial of Bevacizumab Plus Interferon Alfa-2a in Patients With Metastatic Renal Cell Carcinoma (AVOREN): Final Analysis of Overall Survival
    2010 632 citations Joaquim Bellmunt et al. Journal of Clinical Oncology profile →
  8. Phase III Trial of Vinflunine Plus Best Supportive Care Compared With Best Supportive Care Alone After a Platinum-Containing Regimen in Patients With Advanced Transitional Cell Carcinoma of the Urothelial Tract
    2009 543 citations Joaquim Bellmunt, Gedske Daugaard et al. Journal of Clinical Oncology profile →
  9. Randomized Phase II/III Trial Assessing Gemcitabine/Carboplatin and Methotrexate/Carboplatin/Vinblastine in Patients With Advanced Urothelial Cancer Who Are Unfit for Cisplatin-Based Chemotherapy: EORTC Study 30986
    2011 523 citations Maria De Santis, Joaquim Bellmunt et al. Journal of Clinical Oncology profile →
  10. Treatment of Patients With Metastatic Urothelial Cancer “Unfit” for Cisplatin-Based Chemotherapy
    2011 457 citations Matthew D. Galsky, Noah M. Hahn et al. Journal of Clinical Oncology profile →
  11. Guidelines on Prostate Cancer
    2013 438 citations Joaquim Bellmunt et al. profile →
  12. Comprehensive Meta-analysis of Key Immune-Related Adverse Events from CTLA-4 and PD-1/PD-L1 Inhibitors in Cancer Patients
    2017 369 citations Guillermo de Velasco, Youjin Je et al. Cancer Immunology Research profile →
  13. Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer
    2012 367 citations Joaquim Bellmunt, Ana Rovira et al. Nature Medicine profile →
  14. Bladder cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
    2021 309 citations Joaquim Bellmunt, Maria De Santis et al. profile →
  15. Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up
    2019 306 citations Joaquim Bellmunt, Daniel P. Petrylak et al. profile →
  16. Adjuvant Chemotherapy for Invasive Bladder Cancer: A 2013 Updated Systematic Review and Meta-Analysis of Randomized Trials
    2013 277 citations Jeffrey J. Leow, William Martin‐Doyle et al. European Urology profile →
  17. Avelumab First-Line Maintenance for Advanced Urothelial Carcinoma: Results From the JAVELIN Bladder 100 Trial After ≥2 Years of Follow-Up
    2023 118 citations Thomas Powles, Se Hoon Park et al. Journal of Clinical Oncology profile →
  18. ESMO Clinical Practice Guideline interim update on first-line therapy in advanced urothelial carcinoma
    2024 74 citations Thomas Powles, Joaquim Bellmunt et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Joaquim Bellmunt United States 77 15.7k 13.6k 12.1k 5.9k 3.9k 651 30.8k
Cora N. Sternberg United States 76 10.6k 0.7× 12.1k 0.9× 21.0k 1.7× 7.6k 1.3× 6.6k 1.7× 583 34.5k
John C. Cheville United States 82 7.9k 0.5× 7.5k 0.6× 16.6k 1.4× 12.5k 2.1× 5.1k 1.3× 511 27.6k
Bradley C. Leibovich United States 81 7.1k 0.5× 6.0k 0.4× 17.9k 1.5× 11.1k 1.9× 3.9k 1.0× 456 24.4k
Daniel P. Petrylak United States 63 7.5k 0.5× 11.1k 0.8× 10.7k 0.9× 4.9k 0.8× 3.4k 0.9× 529 23.1k
Ronald de Wit Netherlands 67 9.2k 0.6× 10.2k 0.8× 13.4k 1.1× 4.5k 0.8× 4.5k 1.1× 373 26.4k
Michael L. Blute United States 100 9.7k 0.6× 6.6k 0.5× 28.4k 2.3× 13.0k 2.2× 4.6k 1.2× 507 36.2k
Dean F. Bajorin United States 73 15.6k 1.0× 8.0k 0.6× 4.9k 0.4× 4.2k 0.7× 1.4k 0.3× 492 21.4k
R. Houston Thompson United States 69 5.5k 0.4× 4.8k 0.4× 12.6k 1.0× 7.6k 1.3× 2.3k 0.6× 424 18.5k
Stephen A. Boorjian United States 72 9.3k 0.6× 3.9k 0.3× 12.2k 1.0× 6.4k 1.1× 2.2k 0.6× 569 20.8k
J. Alfred Witjes Netherlands 81 17.5k 1.1× 4.1k 0.3× 9.6k 0.8× 4.2k 0.7× 2.0k 0.5× 407 27.9k

Countries citing papers authored by Joaquim Bellmunt

Since Specialization
Citations

This map shows the geographic impact of Joaquim Bellmunt's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Joaquim Bellmunt with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Joaquim Bellmunt more than expected).

Fields of papers citing papers by Joaquim Bellmunt

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Joaquim Bellmunt. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Joaquim Bellmunt. The network helps show where Joaquim Bellmunt may publish in the future.

Co-authorship network of co-authors of Joaquim Bellmunt

This figure shows the co-authorship network connecting the top 25 collaborators of Joaquim Bellmunt. A scholar is included among the top collaborators of Joaquim Bellmunt based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Joaquim Bellmunt. Joaquim Bellmunt is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Castelo, Robert, et al.. (2025). Predicting immunotherapy response of advanced bladder cancer through a meta-analysis of six independent cohorts. Nature Communications. 16(1). 1213–1213. 4 indexed citations
2.
Bellmunt, Joaquim, Júlia Perera‐Bel, Gardenia Vargas‐Parra, et al.. (2025). Prognostic Value of PARP1 and PARP2 Copy Number Alterations in Prostate Cancer. Laboratory Investigation. 105(6). 104171–104171.
3.
Jiang, Changying, Omar Alhalabi, Amanda Nizam, et al.. (2024). 8P Factors associated with primary progression in patients with advanced urothelial carcinoma (aUC) treated with enfortumab vedotin (EV): Analysis of the UNITE study. ESMO Open. 9. 102263–102263. 1 indexed citations
4.
Sadeghi, Sarmad, Nataliya Mar, Denice Tsao‐Wei, et al.. (2024). Association of ephrinB2 (B2) expression on overall survival (OS) and resistance to PD1/L1 inhibitors (inh) in metastatic urothelial carcinoma (mUC).. Journal of Clinical Oncology. 42(16_suppl). 4577–4577.
5.
Bellmunt, Joaquim, Thomas Powles, Se Hoon Park, et al.. (2024). Avelumab first-line maintenance (1LM) for advanced urothelial carcinoma (aUC): Long-term outcomes from JAVELIN Bladder 100 in patients (pts) with low tumor burden.. Journal of Clinical Oncology. 42(16_suppl). 4566–4566. 3 indexed citations
6.
McGregor, Bradley A., Lucia Kwak, Guru Sonpavde, et al.. (2024). Sacituzumab govitecan (SG) plus enfortumab vedotin (EV) for metastatic urothelial carcinoma (mUC) treatment-experienced (DAD) and with pembrolizumab (P) in treatment naïve UC (DAD-IO).. Journal of Clinical Oncology. 42(16_suppl). TPS4618–TPS4618. 2 indexed citations
7.
Powles, Thomas, Zoe J. Assaf, Viraj Degaonkar, et al.. (2023). Updated Overall Survival by Circulating Tumor DNA Status from the Phase 3 IMvigor010 Trial: Adjuvant Atezolizumab Versus Observation in Muscle-invasive Urothelial Carcinoma. European Urology. 85(2). 114–122. 61 indexed citations
8.
Powles, Thomas, Se Hoon Park, Claudia Caserta, et al.. (2023). Avelumab First-Line Maintenance for Advanced Urothelial Carcinoma: Results From the JAVELIN Bladder 100 Trial After ≥2 Years of Follow-Up. Journal of Clinical Oncology. 41(19). 3486–3492. 118 indexed citations breakdown →
9.
Powles, Thomas, Srikala S. Sridhar, Yohann Loriot, et al.. (2021). Avelumab maintenance in advanced urothelial carcinoma: biomarker analysis of the phase 3 JAVELIN Bladder 100 trial. Nature Medicine. 27(12). 2200–2211. 74 indexed citations
10.
Rodríguez‐Vida, Alejo, Núria Juanpere, Oriol Arpí, et al.. (2019). Novel Oral mTORC1/2 Inhibitor TAK-228 Has Synergistic Antitumor Effects When Combined with Paclitaxel or PI3Kα Inhibitor TAK-117 in Preclinical Bladder Cancer Models. Molecular Cancer Research. 17(9). 1931–1944. 27 indexed citations
11.
Nassar, Amin H., Renato Umeton, Jaegil Kim, et al.. (2018). Mutational Analysis of 472 Urothelial Carcinoma Across Grades and Anatomic Sites. Clinical Cancer Research. 25(8). 2458–2470. 87 indexed citations
12.
McKay, Rana R., Dominick Bossé, Kathryn P. Gray, et al.. (2018). Radium-223 Dichloride in Combination with Vascular Endothelial Growth Factor–Targeting Therapy in Advanced Renal Cell Carcinoma with Bone Metastases. Clinical Cancer Research. 24(17). 4081–4088. 26 indexed citations
13.
Velasco, Guillermo de, Youjin Je, Dominick Bossé, et al.. (2017). Comprehensive Meta-analysis of Key Immune-Related Adverse Events from CTLA-4 and PD-1/PD-L1 Inhibitors in Cancer Patients. Cancer Immunology Research. 5(4). 312–318. 369 indexed citations breakdown →
14.
Teo, Min Yuen, Richard Bambury, Emily C. Zabor, et al.. (2017). DNA Damage Response and Repair Gene Alterations Are Associated with Improved Survival in Patients with Platinum-Treated Advanced Urothelial Carcinoma. Clinical Cancer Research. 23(14). 3610–3618. 189 indexed citations
15.
Martin‐Doyle, William, Jeffrey J. Leow, Anna Orsola, Steven L. Chang, & Joaquim Bellmunt. (2015). Improving Selection Criteria for Early Cystectomy in High-Grade T1 Bladder Cancer: A Meta-Analysis of 15,215 Patients. Journal of Clinical Oncology. 33(6). 643–650. 142 indexed citations
16.
17.
Meeks, Joshua J., Joaquim Bellmunt, Bernard H. Bochner, et al.. (2012). A Systematic Review of Neoadjuvant and Adjuvant Chemotherapy for Muscle-invasive Bladder Cancer. European Urology. 62(3). 523–533. 168 indexed citations
18.
Bellmunt, Joaquim, Gerhardt Attard, Amit Bahl, et al.. (2012). Advances in the management of high‐risk localised and metastatic prostate cancer. British Journal of Urology. 109(s2). 8–13. 7 indexed citations
19.
Santis, Maria De, Joaquim Bellmunt, Graham M. Mead, et al.. (2011). Randomized Phase II/III Trial Assessing Gemcitabine/Carboplatin and Methotrexate/Carboplatin/Vinblastine in Patients With Advanced Urothelial Cancer Who Are Unfit for Cisplatin-Based Chemotherapy: EORTC Study 30986. Journal of Clinical Oncology. 30(2). 191–199. 523 indexed citations breakdown →
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Cora N. Sternberg Breakdown of academic impact, for papers by John C. Cheville Breakdown of academic impact, for papers by Bradley C. Leibovich Breakdown of academic impact, for papers by Daniel P. Petrylak Breakdown of academic impact, for papers by Ronald de Wit Breakdown of academic impact, for papers by Michael L. Blute Breakdown of academic impact, for papers by Dean F. Bajorin Breakdown of academic impact, for papers by R. Houston Thompson Breakdown of academic impact, for papers by Stephen A. Boorjian Breakdown of academic impact, for papers by J. Alfred Witjes
Rankless by CCL
2026